Currently Viewing:
Newsroom
Currently Reading
Repurposing Statins for Treatment of Ovarian Cancer
March 29, 2016 – AJMC Staff
Legislators Urge HHS and NIH to Intervene With the Price of Enzalutamide
March 29, 2016 – Surabhi Dangi-Garimella, PhD
Hospital Stay Did Not Improve Survival Among Terminal Cancer Patients in Japan
March 28, 2016 – Surabhi Dangi-Garimella, PhD
This Week in Managed Care: March 26, 2016
March 26, 2016
Drug Manufacturers Lack in Oncology Provider Engagement
March 25, 2016 – Surabhi Dangi-Garimella, PhD
Medicare Advantage Plans Have Lower Hospitalizations Than Medicare FFS Plans
March 25, 2016 – Brenna Diaz
Oncotype DX Test for Breast Cancer Finds Clinical Acceptance, but Disparity Exists
March 24, 2016 – Surabhi Dangi-Garimella, PhD
What We're Reading: Valeant Increases Aid-in-Dying Drug Price Ahead of California's New Law
March 24, 2016 – AJMC Staff
Chemotherapy's Lasting Impact on Male Fertility in Childhood Cancer Survivors
March 23, 2016 – Surabhi Dangi-Garimella, PhD

Repurposing Statins for Treatment of Ovarian Cancer

AJMC Staff
A study presented at the 47th Society of Gynecologic Oncology meeting held in San Diego, found that women with ovarian cancer who received statin therapy in tandem with their cancer treatment had better survival.
A study presented at the 47th Society of Gynecologic Oncology meeting held in San Diego, found that women with ovarian cancer who received statin therapy in tandem with their cancer treatment had better survival.

An analysis of Medicare claims data, found that statin use resulted in a 34% reduction in survival hazard among 1510 Medicare-age women (P < .0001), specifically in those who were treated with lipophilic statin agents. At moderate to high doses.

For this study, the authors used Medicare-linked data from the National Cancer Institute Surveillance, Epidemiology, and End Results program for newly diagnosed epithelial ovarian cancer during 2007 to 2009. Statin use was defined by an existing prescription at the time of surgery or a new prescription after surgery. The data showed that 636 of the 1,510 patients qualified as statin users during the study period. The statin of choice was a lipophilic agent in 88.7% of cases -- atorvastatin (Lipitor), lovastatin (Mevacor), or simvastatin (Zocor). Dosage was moderate in 70.4% of statin users and high in 15.3%.

According to the report in Medpage Today, statin users had a median overall survival (OS) of 32.2 months versus 28.7 months for non-users (P < .001). Patients with stage III disease had a greater survival benefit with statin use (31.7 versus 25.9 months, P < .001). The statin benefit applied to patients with serous (HR 0.69, 95% CI, 0.55-0.87, P = .002) and nonserous tumors (OR 0.33-0.82, P = .005).

Moderate-dose therapy was associated with a 40% reduction in the survival hazard (P < .0001) and high-dose therapy with a 33% reduction (P = .04). Patients on low-dose statin therapy had survival similar to that of nonusers.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up